Exploiting novel molecular targets in gastrointestinal cancers

Wen W. Ma, Manuel Hidalgo

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.

Original languageEnglish (US)
Pages (from-to)5845-5856
Number of pages12
JournalWorld journal of gastroenterology
Issue number44
StatePublished - Nov 28 2007


  • Angiogenesis
  • Colorectal
  • Epidermal growth factor receptor
  • Liver cancers
  • Pancreatic
  • Targeted therapy
  • mTOR

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Exploiting novel molecular targets in gastrointestinal cancers'. Together they form a unique fingerprint.

Cite this